Impact of Anti-TNF α Treatment on Persistent Non-Infectious Uveitis in Children in Saudi Arabia
By
Abeer Aljahdali
Abrar A. Alhawsawi
Maram Alenazi
Moustafa S. Magliyah
Hassan Al-Dhibi
January 17, 2026
Clinical Scorecard: Impact of Anti-TNF α Treatment on Persistent Non-Infectious Uveitis in Children in Saudi Arabia
At a Glance
Category Detail
Condition Persistent Non-Infectious Uveitis in Children Key Mechanisms Anti-TNF-α therapies reduce inflammation and complications associated with uveitis. Target Population Children diagnosed with refractory non-infectious uveitis. Care Setting Tertiary eye hospital in Saudi Arabia.
Key Highlights
Pediatric uveitis accounts for less than 10% of all uveitis cases but has a high risk of complications. Anti-TNF-α medications like Infliximab and Adalimumab are effective in treating refractory cases. The study included 32 patients with a mean follow-up duration of 7.6 years. Guideline-Based Recommendations
Diagnosis
Use the Standardization of Uveitis Nomenclature (SUN) Classification Scale for diagnosis. Management
Initiate treatment with anti-TNF-α medications for refractory cases not responsive to conventional immunosuppressants. Monitoring & Follow-up
Regular follow-ups to assess best corrected visual acuity (BCVA) and inflammatory activity. Risks
Monitor for potential complications from prolonged corticosteroid use. Patient & Prescribing Data
Children aged ≤ 18 years with refractory non-infectious uveitis.
Anti-TNF-α therapies have shown significant improvements in managing chronic uveitis.
Clinical Best Practices
Conduct a thorough uveitis workup to determine the cause and type of uveitis. Utilize multimodal imaging for assessment and monitoring of ocular complications. Ensure compliance with prescribed medications and monitor for side effects. Related Resources & Content
